Peregrine Pharmaceuticals (PPHM) 0.5599 -0.025

Peregrine Pharmaceuticals, Inc.
(PPHM) 0.5599 -0.025

Last Trade:	0.55	Day Range:	0.55 - 0.59
Trade Time:	08:05PM	52wk Range:	0.39 - 2.27
Prev. Close:	0.575	Market Cap:	54.38M
Open:	0.5749	Div Yield:
Volume:	674599	PE:
EPS:	-0.55

The Latest On PPHM

Peregrine Announces Positive Top-Line Data From Randomized, Double-Blind Bavituximab Phase II Trial in Second-Line Non-Small Cell Lung Cancer 5/21/12 7:31am

Peregrine Pharma Minimum Bid Notice 3/28/12 4:01pm

Peregrine Reports Data From Phase II Front-Line Lung Cancer Trial; Promising Progression-Free Survival From Site Assessments 3/9/12 9:01am

UPDATE: Peregrine Says Preliminary Data From Phase II Study Shows Antiviral Activity and Positive Safety Profile at Both Bavituximab Doses Evaluated 12/29/11 9:02am

Peregrine Provides Update on HCV Clinical Program 12/29/11 9:00am

Investor Ideas: Tuesday's Biotech and Pharma Stocks to Watch 12/7/11 2:31pm

Microcap Movers for Tuesday December 6, 2011 12/6/11 6:47pm

Is This Drug About to Cure Cancer? 12/6/11 3:32pm

Peregrine's Bavituximab Shows 50% Improvement in Overall Tumor Response Rate in Randomized Phase II Lung Cancer Trial 12/6/11 9:04am

Peregrine Reports Promising 23.2 Month Median Overall Survival From Phase II Advanced Breast Cancer Trial 11/22/11 9:01am

Peregrine Completes Patient Enrollment in Second-Line Non-Small Cell Lung Cancer Trial; Data to Be Unblinded in First Half 2012 10/6/11 8:03am

Peregrine Completes Patient Enrollment in Randomized Phase II HCV Trial for Bavituximab 9/26/11 8:07am

Peregrine Announces Positive Top-Line Data From Randomized, Double-Blind Bavituximab Phase II Trial in Second-Line Non-Small Cell Lung Cancer 5/21/12

Peregrine Pharma Minimum Bid Notice 3/28/12

Peregrine Reports Data From Phase II Front-Line Lung Cancer Trial; Promising Progression-Free Survival From Site Assessments 3/9/12

UPDATE: Peregrine Says Preliminary Data From Phase II Study Shows Antiviral Activity and Positive Safety Profile at Both Bavituximab Doses Evaluated 12/29/11

Peregrine Provides Update on HCV Clinical Program 12/29/11

Investor Ideas: Tuesday's Biotech and Pharma Stocks to Watch 12/7/11

Microcap Movers for Tuesday December 6, 2011 12/6/11

Is This Drug About to Cure Cancer? 12/6/11

Peregrine's Bavituximab Shows 50% Improvement in Overall Tumor Response Rate in Randomized Phase II Lung Cancer Trial 12/6/11

Peregrine Reports Promising 23.2 Month Median Overall Survival From Phase II Advanced Breast Cancer Trial 11/22/11

Peregrine Completes Patient Enrollment in Second-Line Non-Small Cell Lung Cancer Trial; Data to Be Unblinded in First Half 2012 10/6/11

Peregrine Completes Patient Enrollment in Randomized Phase II HCV Trial for Bavituximab 9/26/11

Microcap Movers for Tuesday December 6, 2011 12/6/11

Is This Drug About to Cure Cancer? 12/6/11

Buy This Cancer Stock Today (PPHM) 6/24/10

Puts Sold on Peregrine Pharmaceuticals (PPHM) 6/24/10

McNicoll, Lewis & Vlak Maintains Peregrine Pharmaceuticals Buy, PT 9/8/11

McNicoll, Lewis & Vlak Maintains Peregrine Pharmaceuticals Buy, PT 8/24/11

UPDATE: MLV Lowers PT on Peregrine Pharmaceuticals to $8.50 7/18/11

Life Tech Capital Reiterates Strong Buy on Peregrine Pharma (PPHM) 12/14/10

Initiated BUY on Peregrine Pharmaceuticals (PPHM) 4/14/10

Trade PPHM
NOW!

Partner Headlines

A Light at the End of the Tunnel: MRNA, PPHM, and GRVY Under the Microscope 5/29/12

Acacia Research Corporation, Ixia Among Stocks Gapping Up Friday 4/20/12

For Biotech, 'Fail' is Making a Big Comeback 3/12/12

Peregrine Pharmaceuticals Inc. Reports Operating Results (10-Q) 3/9/12

Peregrine Pharma Cancer Drug Unmasked by Independent Review 3/9/12

Biotech Roundup: What Now for Peregrine (PPHM), BioSante (BPAX), and CEL-SCI (CVM)? 2/7/12

Peregrine Pharmaceuticals Inc. Reports Operating Results (10-Q) 12/12/11

Biotech Stock Mailbag: YM Bio, Exact, Peregrine 12/9/11

Company News for December 7, 2011 - Corporate Summary 12/7/11

5 Stocks Poised for Breakouts 11/7/11

Press Releases

PPHM, TNGN and SAPX are the Daily Market Movers for December 6th from OTCPicks.com 12/6/11 Emailwire

RITT, AMWI and PPHM are the Stocks to Watch for December 7th from OTCPicks.com 12/6/11 Emailwire

Get the latest PPHM stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Peregrine Pharmaceuticals, Inc. stock price.

Peregrine Pharmaceuticals, Inc. by YCharts

Peregrine Pharmaceuticals (PPHM) 0.5599 -0.025

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On PPHM

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social